Loading company…
Pelage Pharmaceuticals develops medicines aimed at treating hair loss and related conditions.
Pelage Pharmaceuticals develops treatments for hair loss, including androgenetic alopecia and chemotherapy-induced alopecia, using a small-molecule platform targeting hair follicle stem cells. Founded in 2018 and based in Los Angeles, US, it raised USD 120 million in Series B funding in October 2025, co-led by ARCH Venture Partners and GV, with other investors participating. The company planned to advance clinical development of PP405.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in